[go: up one dir, main page]

EP3589272A4 - Procédés pour prévenir par prophylaxie, ralentir l'évolution ou traiter la maladie d'alzheimer - Google Patents

Procédés pour prévenir par prophylaxie, ralentir l'évolution ou traiter la maladie d'alzheimer Download PDF

Info

Publication number
EP3589272A4
EP3589272A4 EP18761409.4A EP18761409A EP3589272A4 EP 3589272 A4 EP3589272 A4 EP 3589272A4 EP 18761409 A EP18761409 A EP 18761409A EP 3589272 A4 EP3589272 A4 EP 3589272A4
Authority
EP
European Patent Office
Prior art keywords
slowing
progression
disease
methods
treating alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP18761409.4A
Other languages
German (de)
English (en)
Other versions
EP3589272A1 (fr
Inventor
Hollis Bryan BREWER, Jr.
Michael M. MATIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HDL Therapeutics Inc
Original Assignee
HDL Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/876,808 external-priority patent/US20190021674A1/en
Application filed by HDL Therapeutics Inc filed Critical HDL Therapeutics Inc
Priority claimed from PCT/US2018/020502 external-priority patent/WO2018160868A1/fr
Publication of EP3589272A1 publication Critical patent/EP3589272A1/fr
Publication of EP3589272A4 publication Critical patent/EP3589272A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Developmental Disabilities (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
EP18761409.4A 2017-03-01 2018-03-01 Procédés pour prévenir par prophylaxie, ralentir l'évolution ou traiter la maladie d'alzheimer Ceased EP3589272A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762465262P 2017-03-01 2017-03-01
US201762516100P 2017-06-06 2017-06-06
US201762537581P 2017-07-27 2017-07-27
US15/876,808 US20190021674A1 (en) 2017-01-23 2018-01-22 Methods for Treating Cholesterol-Related Diseases
PCT/US2018/020502 WO2018160868A1 (fr) 2017-03-01 2018-03-01 Procédés pour prévenir par prophylaxie, ralentir l'évolution ou traiter la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
EP3589272A1 EP3589272A1 (fr) 2020-01-08
EP3589272A4 true EP3589272A4 (fr) 2020-11-25

Family

ID=67682480

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18761409.4A Ceased EP3589272A4 (fr) 2017-03-01 2018-03-01 Procédés pour prévenir par prophylaxie, ralentir l'évolution ou traiter la maladie d'alzheimer

Country Status (5)

Country Link
EP (1) EP3589272A4 (fr)
JP (2) JP2020509036A (fr)
CN (1) CN110545797A (fr)
AU (1) AU2018226803A1 (fr)
CA (1) CA3053491A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3790573A4 (fr) * 2018-05-11 2022-05-11 HDL Therapeutics, Inc. Procédés de prévention prophylactique, de ralentissement de l'évolution ou de traitement de l'angiopathie amyloïde cérébrale, de la maladie d'alzheimer et/ou d'un accident vasculaire cérébral aigu
CN116662835A (zh) * 2022-02-18 2023-08-29 医疗研究开发有限公司 分层方法以及分层装置

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106556A1 (en) * 2002-08-26 2004-06-03 Yanhong Zhu Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles
US20050004004A1 (en) * 2003-07-03 2005-01-06 Marc Bellotti Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20080146642A1 (en) * 2006-10-12 2008-06-19 Xianqi Kong Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US9580494B2 (en) * 2007-05-14 2017-02-28 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103845A2 (fr) * 2007-02-23 2008-08-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services. Anticorps monoclonaux neutralisant les toxines de l'anthrax

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106556A1 (en) * 2002-08-26 2004-06-03 Yanhong Zhu Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles
US20050004004A1 (en) * 2003-07-03 2005-01-06 Marc Bellotti Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20080146642A1 (en) * 2006-10-12 2008-06-19 Xianqi Kong Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US9580494B2 (en) * 2007-05-14 2017-02-28 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRUNO P IMBIMBO: "Beta-amyloid immunization approaches for Alzheimer's disease", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 56, 1 January 2002 (2002-01-01), pages 150 - 162, XP002426086, ISSN: 0272-4391, DOI: 10.1002/DDR.10070 *

Also Published As

Publication number Publication date
CA3053491A1 (fr) 2018-09-07
AU2018226803A1 (en) 2019-08-29
CN110545797A (zh) 2019-12-06
JP2020509036A (ja) 2020-03-26
JP2023071648A (ja) 2023-05-23
EP3589272A1 (fr) 2020-01-08

Similar Documents

Publication Publication Date Title
EP3645121B8 (fr) Méthodes de traitement de la maladie de huntington
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3268086A4 (fr) Lsd pour le traitement de la maladie d'alzheimer
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
EP3448874A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3484504A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3386511A4 (fr) Méthodes de traitement de la maladie de huntington
EP3140403A4 (fr) Prévention et traitement de la maladie d'alzheimer par édition du génome à l'aide du système crispr/cas
WO2017044807A3 (fr) Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
EP3261446A4 (fr) Méthodes et compositions permettant le traitement ou la prévention de la maladie de parkinson
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
EP3820477A4 (fr) Composés, compositions et procédés pour le traitement d'une maladie
EP3589272A4 (fr) Procédés pour prévenir par prophylaxie, ralentir l'évolution ou traiter la maladie d'alzheimer
HK1243709A1 (zh) 可用於治疗阿尔茨海默氏病的四氢呋喃稠合的氨基氢噻嗪衍生物
EP3646872A4 (fr) Agent pour la prévention et/ou le traitement de la maladie d'alzheimer
EP3707507A4 (fr) Méthodes de pronostic ou de traitement de la maladie de parkinson
EP3634979A4 (fr) Compositions et procédés de traitement de la maladie d'alzheimer
EP3244897A4 (fr) Procédés pour le traitement de la maladie d'alzheimer
EP3448377A4 (fr) Méthodes pour le traitement d'une infection
EP3119402A4 (fr) Dérivés d'oestradiol substitués en 6 pour le traitement de la maladie d'alzheimer
EP3601570A4 (fr) Méthodes de traitement de la maladie d'alzheimer
HK40103246A (zh) 亨廷顿病的aav治疗

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190828

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009127000

Ipc: A61K0038180000

A4 Supplementary search report drawn up and despatched

Effective date: 20201028

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/18 20060101AFI20201022BHEP

Ipc: A61K 38/30 20060101ALI20201022BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210917

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20230407